A randomized, double-blind, placebo managed, stage III scientific trial evaluated the efficacy and safety profile of adalimumab being a monotherapy in patients with RA who had unsuccessful to answer csDMARDs [191]. The outcomes confirmed both statistically considerable improvement within the condition action and a very good basic safety profile. Nonetheless, https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/